Autolus Therapeutics Statistics
Want to see AUTL full AI Analyst Report?
Autolus Therapeutics (AUTL) Stock Statistics & Valuation Metrics
Total Valuation
Autolus Therapeutics has a market cap or net worth of $351.33M. The enterprise value is $707.73M.
- Market Cap
- $351.33M
- Enterprise Value
- $707.73M
Share Statistics
Autolus Therapeutics has 266,162,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 266,162,540
- Owned by Insiders
- <0.01%
- Owned by Institutions
- 8.83%
Financial Efficiency
Autolus Therapeutics’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -51.54%.
- Return on Equity (ROE)
- -1.62
- Return on Assets (ROA)
- -0.49
- Return on Invested Capital (ROIC)
- -51.54%
- Return on Capital Employed (ROCE)
- -0.55
- Revenue Per Employee
- 100.48K
- Profits Per Employee
- -383.24K
- Employee Count
- 752
- Asset Turnover
- 0.13
- Inventory Turnover
- 2.91
Valuation Ratios
The current PE Ratio of Autolus Therapeutics is -1.36. Autolus Therapeutics’s PEG ratio is 0.06.
- PE Ratio
- -1.36
- PS Ratio
- 2.56
- PB Ratio
- 12.83
- Price to FCF
- -1.76
- Price to Operating Cash Flow
- -1.99
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 75.56M and earned -288.20M in profits. Earnings per share was -1.08.
- Revenue
- 75.56M
- Gross Profit
- -21.03M
- Operating Income
- -281.44M
- Pretax Income
- -296.85M
- Net Income
- -288.20M
- EBITDA
- -250.28M
- Earnings Per Share (EPS)
- -1.08
Cash Flow
In the last 12 months, operating cash flow was -176.24M and capital expenditures -28.61M, giving a free cash flow of -204.85M billion.
- Operating Cash Flow
- -176.24M
- Free Cash Flow
- -204.85M
- Free Cash Flow per Share
- -0.75
Dividends & Yields
Autolus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -71.09%
- Earnings Yield
- -83.83%
Stock Price Statistics
- Beta
- 1.95
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 1.80
- 200-Day Moving Average
- 1.67
- Relative Strength Index (RSI)
- 31.42
- Average Volume (3m)
- 2.14M
Important Dates
Autolus Therapeutics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Autolus Therapeutics as a current ratio of 5.94, with Debt / Equity ratio of 197.38%
- Current Ratio
- 5.94
- Quick Ratio
- 5.48
- Debt to Market Cap
- 0.54
- Net Debt to EBITDA
- -0.99
- Interest Coverage Ratio
- -7.66
Taxes
In the past 12 months, Autolus Therapeutics has paid -8.65M in taxes.
- Income Tax
- -8.65M
- Effective Tax Rate
- 0.03
Enterprise Valuation
Autolus Therapeutics EV to EBITDA ratio is -1.11, with an EV/FCF ratio of -1.04.
- EV to Sales
- 2.10
- EV to EBITDA
- -1.11
- EV to Free Cash Flow
- -1.04
- EV to Operating Cash Flow
- -1.09
Balance Sheet
Autolus Therapeutics has $248.38M in cash and marketable securities with $147.87M in debt, giving a net cash position of $100.50M billion.
- Cash & Marketable Securities
- $248.38M
- Total Debt
- $147.87M
- Net Cash
- $100.50M
- Net Cash Per Share
- $0.38
- Tangible Book Value Per Share
- $0.04
Margins
Gross margin is 35.77%, with operating margin of -159.57%, and net profit margin of -186.32%.
- Gross Margin
- 35.77%
- Operating Margin
- -159.57%
- Pretax Margin
- -186.57%
- Net Profit Margin
- -186.32%
- EBITDA Margin
- -145.37%
- EBIT Margin
- -119.49%
Analyst Forecast
The average price target for Autolus Therapeutics is $8.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $8.33
- Price Target Upside
- 531.31% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 167.93%
- EPS Growth Forecast
- -13.79%
Scores
- Smart Score
- 6
- AI Score
- 45
